NCT04845178Phase 2Completed

Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

Study sponsor: AEON Biopharma, Inc. · AEON

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2024-06-19Actual

Enrollment · participants797Actual

Source updated2024-09-04Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Migraine

Treatments or interventions studied

ABP-450DrugAlso known as prabotulinumtoxinA
PlaceboDrugAlso known as 0.9% sodium chloride, saline

Primary outcomes · main study measures

Read the study measures

measure: Change in Monthly Migraine Days; description: The primary efficacy endpoint will be the change in mean Monthly Migraine Days (MMD) from the 4-week Baseline period to Weeks 21 to 24 Treatment period.; timeFrame: Baseline to Weeks 21 to 24 Treatment period.; measure: Incidence of Treatment Emergent Adverse Events; description: The primary safety endpoint will be the incidence of TEAEs throughout the study when dosed with placebo, ABP-450 (low dose), or ABP-450 (high dose).; timeFrame: Baseline to Week 28 - End of Study.

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history